Iron Dyshomeostasis in MSA Pathogenesis Experiment

• 1. MSA patients will demonstrate >2-fold elevation in brain iron deposition (QSM values) in putamen and substantia nigra compared to controls (p<0.001)
• 2. Serum hepcidin levels will correlate inversely with disease severity (UMSARS scores, r>0.6) and predict clinical progression over 12 months
• 3. Iron chelation therapy will slow clinical progression by >25% compared to placebo (effect size d>0.7) with corresponding reduction in brain iron on MRI
• 4. Iron biomarkers will demonstrate >80% accuracy in differentiating MSA from PD using ROC analysis (AUC>0.8)
• 5.

• 1. MSA patients will demonstrate >2-fold elevation in brain iron deposition (QSM values) in putamen and substantia nigra compared to controls (p<0.001)
• 2. Serum hepcidin levels will correlate inversely with disease severity (UMSARS scores, r>0.6) and predict clinical progression over 12 months
• 3. Iron chelation therapy will slow clinical progression by >25% compared to placebo (effect size d>0.7) with corresponding reduction in brain iron on MRI
• 4. Iron biomarkers will demonstrate >80% accuracy in differentiating MSA from PD using ROC analysis (AUC>0.8)
• 5. Postmortem validation will show significant co-localization of iron deposits with alpha-synuclein inclusions in >70% of MSA cases

Primary Statistical Success Criteria

Achievement of statistical significance (p<0.05, two-tailed) for the primary endpoint comparing brain iron deposition between MSA patients and controls using quantitative susceptibility mapping (QSM) values in the putamen and substantia nigra. Secondary statistical success requires demonstration of significant group differences (p<0.05) in serum hepcidin levels, transferrin receptor activity, and CSF iron concentrations via ANOVA with post-hoc Bonferroni correction.

Primary Statistical Success Criteria

Achievement of statistical significance (p<0.05, two-tailed) for the primary endpoint comparing brain iron deposition between MSA patients and controls using quantitative susceptibility mapping (QSM) values in the putamen and substantia nigra. Secondary statistical success requires demonstration of significant group differences (p<0.05) in serum hepcidin levels, transferrin receptor activity, and CSF iron concentrations via ANOVA with post-hoc Bonferroni correction. Effect sizes must reach Cohen's d>0.8 for group comparisons, indicating robust biological differences. Multivariate analysis using general linear models controlling for age, sex, disease duration, and apolipoprotein E genotype must confirm iron biomarker associations independently of confounding variables.

Clinical and Retention Success Metrics

Maintenance of >85% participant retention through the 18-month observational phase (Phases 1-2), defined as completion of ≥4 of 6 scheduled study visits with complete clinical and biomarker assessments. Successful recruitment and baseline characterization of all 120 participants (40 MSA, 40 PD, 40 controls) within the 6-month enrollment window, with documented diagnosis confirmation via consensus criteria. For Phase 3 iron chelation pilot, achievement of <20% dropout rate due to deferiprone-related adverse events, with adverse event incidence not exceeding 40% in the active treatment arm compared to historical literature rates of 25-30% for this agent.

Biomarker Validation and Predictive Accuracy

Development of a multiparametric iron biomarker panel (incorporating serum hepcidin, transferrin saturation, iron regulatory protein-1 activity in PBMCs, and CSF iron/ferritin ratios) demonstrating ≥80% diagnostic accuracy (area under ROC curve [AUC]>0.8) for differentiating MSA from PD and healthy controls. Serum hepcidin levels must show significant inverse correlation with UMSARS scores (Spearman's r<-0.6, p<0.01) and demonstrate predictive validity for 12-month clinical progression using Cox proportional hazards modeling with hazard ratio >1.8. Iron biomarkers must successfully stratify MSA patients into fast-progressors and slow-progressors with >75% sensitivity and specificity at 6-month follow-up timepoint.

Mechanistic and Postmortem Validation Success

Successful procurement and analysis of postmortem brain tissue from ≥10 MSA cases with ≥10 matched disease and age controls, demonstrating significant co-localization of iron deposits (Prussian blue staining, atomic absorption spectroscopy quantification) with phosphorylated alpha-synuclein inclusions in >70% of MSA cases (p<0.01 vs controls). Immunohistochemical validation must show iron co-localization with oligodendrocyte pathology (CNPase/4-hydroxynonenal staining) in >65% of affected white matter regions. Quantitative analysis of oxidative stress markers (protein carbonyls, 4-hydroxynonenal adducts, 8-OHdG) must correlate significantly with iron burden (r>0.7) and alpha-synuclein pathology scores, supporting mechanistic linkage.

Therapeutic Response and Imaging Success

In the Phase 3 iron chelation pilot (n=20), superiority of deferiprone over placebo in slowing UMSARS progression by ≥25% (effect size d>0.7) over 12 months with p<0.05 on intention-to-treat analysis. Brain iron quantification via QSM must demonstrate significant reduction in putaminal and nigral iron content (≥15% decrease from baseline) in the deferiprone-treated group compared to placebo controls by Month 30. Safety success criteria include maintenance of absolute neutrophil count >1.5×10⁹/L, serum creatinine <1.5× baseline, and absence of serious hepatotoxicity (transaminases <3× upper limit normal) in ≥95% of treated participants.